Ascendis Pharma Inc. (ASND) Company Long-Term Loans and Borrowings

Ascendis Pharma Inc. - graphic logo of issuer ASND

Ascendis Pharma A/S is advancing endocrinology by utilizing its unique TransCon system to safely extend the duration of therapy. This chart on GURU.Markets illustrates the dynamics of the issuer's long-term liabilities, where 0.45 marks a new level. The company generates revenue from the sale of innovative treatments for hypoparathyroidism and growth hormone deficiency, while optimizing R&D costs by outsourcing the final stages of clinical trials.

ASND Ascendis Pharma A/S: Company Long-Term Debts in the range 07/04/2022 - 10/28/2026

Ascendis Pharma Inc. - analytical breakdowns and key metrics (ASND)

- price and consensus price forecast:
Stock Price ascendispharma.com|ASND - Price Target Chart
- market capitalization data:
Market Value Ascendis Pharma|ASND - Total Company Value
- book capitalization data:
Accounting Value per Share Ascendis Pharma|ASND - Book Capitalization|Market Capitalization to Book Value Ratio ascendispharma.com|ASND - Cumulative Company Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Ascendis Pharma A/S|ASND - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Ascendis|ASND - Company Aggregate Debts|Debts to Book Value Ascendis Pharma|ASND - Company Long-Term Liabilities|Amount of Current Liabilities Ascendis Pharma
Fundamental valuation:ASND - ascendispharma.com
Manufactured products of Ascendis Pharma A/S

This metric aggregates all credit obligations of Ascendis Pharma A/S (ASND) with maturities exceeding twelve months. The total amount of long-term liabilities determines the financial leverage and the issuer's ability to service borrowed capital over the long term. For a biotechnology company utilizing outsourced manufacturing, such funds are critical for financing R&D without incurring capital expenditures for plants. The trend in the corporation's long-term loans and borrowings reflects the balance between expansion and solvency.

Competitors of Ascendis Pharma A/S

madrigalpharma.com - Company Long-Term Debts|Company Long-Term Debt Corcept Therapeutics Incorporated (CORT)|RYTM: Company Long-Term Loans and Borrowings|AKRO (Akero Therapeutics Inc) - Company Long-Term Debt|Metsera Therapeutics (MTSR) - Company Long-Term Liabilities|MLTX (MoonLake Immunotherapeutics) - Company Long-Term Debts|Company Long-Term Debts crinetics.com (CRNX)|NewAmsterdam Pharma Company N.V. (NAMS) - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings SLNO (Soleno Therapeutics Inc)|Amicus Pharma - Company Long-Term Debt|Company Long-Term Liabilities 89bio Pharma ETNB|AGIO (Agios Pharmaceuticals) - Company Long-Term Debts|structuretx.com (GPCR) - Long-Term Debt|MDXG - Company Long-Term Liabilities|Rezolute Inc (RZLT) - Amount of Long-Term Liabilities|LXRX (Lexicon Pharma) - Company Long-Term Debts|Company Long-Term Debts MBX Corp|Company Long-Term Debts Altimmune, Inc. (ALT)|Company Long-Term Debt AARD (aardvarktherapeutics.com)|SGMT: Company Long-Term Debt|BioAge Labs - Long-Term Debt|BMEA - Company Long-Term Debt|QNCX - Company Long-Term Debt|Fractyl Health, Inc. - Company Long-Term Debts|VTVT (vTv Therapeutics) - Long-Term Debt Volume|ATPC: Company Long-Term Debt|Long-Term Debt Volume PLUR|Company Long-Term Debt SYBX (Synlogic, Inc.)|Company Long-Term Liabilities Lipocine Corporation (LPCN)|Company Long-Term Debts MTNB (Matinas BioPharma Holdings)|Spruce Biosciences Inc. - Company Long-Term Debts|Company Long-Term Debt GLTO (Galecto)|CTCX - Long-Term Debt Volume|LUMO (Lumos Pharma Corp) - Company Long-Term Debts|Organovo Corp (ONVO) - Company Long-Term Liabilities|Company Long-Term Debts RDUS (Radius Recycling, Inc.)